Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

•      Indications

•      Clinical Trials

•      Efficacy

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      Dosage & Administration

•      FAQs

•      Ventavis Support

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

About Ventavis^® (iloprost)

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• Prostacyclin (PGI₂) functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility.
• Ventavis is an inhaled synthetic prostacyclin which has been shown to
  • Significantly increase patient improvement (improvement in functional class, 10% or greater increase in individual walk distance, and no clinical deterioration) at week 12 of therapy (p=0.0033)^{1,2 †}
  • Significantly improve 6-minute walk distance at week 12 (p<0.01)^{1,2 †}
  • Significantly improve patients' functional class at week 12 (p=0.03)^1,2
• Both functional class III and class IV patients showed improvement by at least one functional class^{1 †}
• Ventavis is used with an inhalation device, the I-neb AAD. It is not used with infusion pumps and catheters.
• No known contraindications¹

^† In controlled trials, Ventavis improved a combined clinical endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of clinical deterioration or death. For more information about Ventavis, please see Full Prescribing Information

Read more about Ventavis:

• Indications
• Clinical Trials
• Efficacy
• Clinical Improvement
• Improved Exercise Capacity
• Functional Class Improvement
• Improved Hemodynamics
• Safety Profile
• Dosage & Administration
• Frequently Asked Questions
• Ventavis Support

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information